Residency · Residency · Preventive Medicine

Commercial Determinants of Health

Introduction

Commercial determinants of health (CDoH) refer to the conditions, actions, and omissions by commercial actors that affect health positively or negatively. The Lancet Series on CDoH (2023) defined them as the "systems, practices, and pathways through which commercial actors drive health and equity". CDoH extend beyond individual products to encompass corporate political activity, marketing, supply chain practices, labor conditions, and environmental impacts. Understanding CDoH is essential for preventive medicine because commercial practices shape the environments in which health behaviors occur, often undermining public health interventions.

Conceptual Framework

Pathways of Commercial Influence on Health

Products and practices: Manufacturing and selling health-harmful commodities (tobacco, alcohol, ultra-processed foods, fossil fuels, opioids) and health-promoting products. Marketing and messaging: Advertising, sponsorships, social media campaigns, and product placement that shape preferences, norms, and consumption patterns. Corporate political activity (CPA): Lobbying, campaign contributions, revolving door appointments, and regulatory capture that shape the policy environment. Supply chains and labor practices: Working conditions, wages, environmental practices, and community impacts throughout production and distribution. Knowledge environment: Industry-funded research, think tanks, and strategic communications that shape scientific discourse and public understanding.

The Industrial Epidemics

Tobacco: Approximately 8 million deaths annually worldwide; the most well-documented case of commercial harm; decades of industry deception about health effects. Alcohol: Approximately 3 million deaths annually; alcohol industry uses tobacco-like tactics to oppose evidence-based policies. Ultra-processed foods: Major driver of the global obesity and NCD epidemic; reformulation, marketing to children, and opposition to labeling/taxation. Fossil fuels: Climate change as a commercial determinant; fossil fuel companies knew about climate risks decades before public disclosure. Pharmaceuticals: Opioid epidemic driven by aggressive marketing of prescription opioids; Purdue Pharma's promotion of OxyContin is a defining case study.

<image>Conceptual framework showing how commercial determinants of health operate through four channels: the market environment (products, pricing, availability, marketing), the policy environment (lobbying, regulatory capture, trade agreements, litigation), the knowledge environment (industry-funded research, think tanks, media influence), and the living and working environment (labor conditions, environmental impact, community investment), all influencing health outcomes at population level</image>

Corporate Political Activity

Strategies and Tactics

Direct lobbying: Health-harmful industries spend billions on lobbying; the pharmaceutical industry alone spent over $350 million annually on U.S. federal lobbying. Campaign contributions: Political donations create access and influence; legislators receiving alcohol industry contributions are less likely to support evidence-based alcohol policies. Revolving door: Movement of personnel between industry and regulatory agencies creates conflicts of interest and regulatory capture. Trade agreements: International trade and investment agreements can be used to challenge domestic health regulations (e.g., tobacco plain packaging challenges under investor-state dispute settlement) Industry self-regulation: Voluntary codes and pledges are often proposed as alternatives to binding regulation; evidence consistently shows self-regulation is insufficient. Legal challenges: Litigation or threats of litigation to delay or block health-protective policies (warning labels, marketing restrictions, taxes)

Case Study: The Tobacco Playbook

Tobacco industry tactics have been adopted by other industries and are collectively known as the "tobacco playbook": Manufacturing doubt about scientific evidence linking products to harm. Funding alternative research to create a body of contradictory evidence. Front groups: Creating seemingly independent organizations to advocate industry positions. Targeting vulnerable populations: Marketing to youth, racial/ethnic minorities, low-income communities, and LGBTQ+ populations. Corporate social responsibility campaigns to improve public image while opposing regulation. International expansion: Shifting marketing and sales to LMICs as regulation tightens in high-income countries.

Marketing and Consumer Behavior

Marketing of Health-Harmful Products

Food industry marketing to children: Children see approximately 10,000 food advertisements annually, predominantly for unhealthy products; self-regulation through the Children's Food and Beverage Advertising Initiative has been largely ineffective. Alcohol marketing: Industry spending exceeds $5 billion annually in the U.S.; digital marketing, influencer partnerships, and sponsorship of sporting events normalize consumption. E-cigarette marketing: JUUL's early marketing directly targeted youth through social media, flavored products, and school-based campaigns; contributed to the youth vaping epidemic. Direct-to-consumer pharmaceutical advertising (DTCA): The U.S. and New Zealand are the only countries permitting DTCA; increases prescribing requests and may promote medicalization of normal conditions.

Digital Marketing and Big Data

Targeted advertising: Algorithms enable precise targeting of health-harmful product marketing based on personal data, browsing history, and psychographic profiles. Influencer marketing: Paid partnerships with social media influencers create perceived peer endorsement of commercial products. Dark marketing: Marketing visible only to targeted individuals, making it difficult to monitor and regulate. Gamification: Using game-like features (rewards, challenges, streaks) to increase product engagement and brand loyalty.

<image>Timeline showing the evolution of tobacco industry tactics from the 1950s (manufacturing doubt about lung cancer link) through the 1990s (Master Settlement Agreement, international expansion), and how these same tactics have been adopted by the alcohol industry (opposing minimum unit pricing), food industry (opposing sugar taxes and labeling), fossil fuel industry (climate denial), and pharmaceutical industry (opioid marketing), with parallel examples at each stage</image>

Policy Responses

Regulatory Approaches

WHO Framework Convention on Tobacco Control (FCTC): First international public health treaty; provisions include marketing bans, plain packaging, tobacco taxation, and smoke-free policies; ratified by 182 parties. Sugar-sweetened beverage taxes: Implemented in over 50 countries/jurisdictions; demonstrate 10-20% reduction in consumption; industry opposition includes massive lobbying and preemption legislation. Alcohol policies: WHO SAFER initiative (Strengthen restrictions on availability, Advance and enforce drink-driving laws, Facilitate access to screening and brief interventions, Enforce bans on advertising, Raise prices through taxation) Front-of-pack labeling: Chile's warning label law reduced purchases of labeled products by 24%; industry-preferred labels (Guideline Daily Amounts) are less effective than interpretive labels. Marketing restrictions: Canada, UK, and other countries have implemented or proposed restrictions on marketing unhealthy foods to children.

Transparency and Accountability

Conflict of interest policies: Excluding industry from health policy-making processes (Article 5.3 of the FCTC for tobacco) Lobbying registries: Mandatory disclosure of lobbying activities and expenditures; vary widely in coverage and enforcement. Research transparency: Disclosure of industry funding for research; policies to prevent biased study design and selective publication. Corporate accountability frameworks: ESG (Environmental, Social, Governance) reporting, human rights due diligence, and accountability for health impacts.

International Trade and Health

Trade liberalization: Can increase availability and marketing of health-harmful products (alcohol, tobacco, ultra-processed foods) in LMICs. Investor-state dispute settlement (ISDS): Mechanisms that allow corporations to challenge domestic health regulations as barriers to trade; Philip Morris challenged Australia's plain packaging law. Regulatory chill: Fear of trade disputes deters countries from implementing health-protective policies. Carve-outs: Health exceptions in trade agreements can protect policy space for public health measures.

Role of Preventive Medicine

Preventive medicine physicians should develop commercial determinant literacy: the ability to recognize, analyze, and respond to commercial influences on health. Policy advocacy: Advocating for evidence-based regulation of health-harmful industries, including taxation, marketing restrictions, and disclosure requirements. Conflict of interest management: Recognizing and managing industry influence in research, education, and clinical practice. Surveillance: Monitoring commercial practices, marketing trends, and industry political activity as part of population health surveillance. Community engagement: Supporting community-led efforts to resist harmful commercial practices and advocate for healthier commercial environments.

<image>Socioecological model adapted for commercial determinants of health, showing how commercial forces operate at every level: individual (targeted marketing, product design for addiction), interpersonal (social norm shaping through advertising, influencer marketing), organizational (workplace food environments, industry-funded continuing education), community (retail density, sponsorship of community events), and policy (lobbying against health regulation, trade agreements, regulatory capture), with specific examples and evidence-based countermeasures at each level</image>

Key Clinical Pearls

The leading risk factors for the global burden of disease (tobacco, alcohol, unhealthy diet, air pollution) are all shaped by commercial determinants; addressing CDoH is therefore central to preventive medicine. The "tobacco playbook" of manufacturing doubt, funding alternative research, lobbying, and targeting vulnerable populations has been adopted by alcohol, food, fossil fuel, and pharmaceutical industries; recognizing these patterns is essential for effective public health advocacy. Industry self-regulation consistently fails to protect public health; binding regulation with enforcement mechanisms is necessary for meaningful change. Preventive medicine physicians have a professional obligation to identify and address conflicts of interest in research, education, and policy, and to advocate for commercial practices that promote rather than undermine health.

References

1. Kickbusch I, Allen L, Franz C. The commercial determinants of health. Lancet Glob Health. 2016;4(12):e895-e896.
2. Gilmore AB, Fabbri A, Baum F, et al. Defining and conceptualising the commercial determinants of health. Lancet. 2023;401(10383):1194-1213.
3. Moodie R, Stuckler D, Monteiro C, et al. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet. 2013;381(9867):670-679.
4. Freudenberg N. Lethal But Legal: Corporations, Consumption, and Protecting Public Health. New York: Oxford University Press; 2014.

Read this lecture as Markdown